Treatment of COVID-19 is heterogeneous across Europe and the world, and evidence for COVID-19 treatment is accumulating rapidly. There is therefore a need for rapid, evidence-based treatment recommendations and information on how best to improve outcomes for hospitalised patients with COVID-19. The new ERS guidelines provide the perfect opportunity to improve knowledge and promote evidence-based practice.
- Learn the key ERS guideline recommendations for management of hospitalised patients with COVID-19.
- Discuss the most recent evidence from clinical trials and the evidence behind treatment decisions.
- Learn about areas of uncertainty in COVID-19 management which may be the focus of future trials or guideline discussions.
Small lectures wrapped in a lively discussion with clinical illustrations:
- What does the term ‘guidelines’ imply, why are guidelines on COVID-19 management needed and how can guidelines be produced in a field moving so quickly?
- What do these guidelines tell us?
- What should be the implications for future research and clinical practice?
- What are the next steps for this living guideline?
- Anti-IL-6 receptor monoclonal antibodies
- Anti-viral drugs, including remdesivir and lopinavir-ritonavir
- Repurposing therapies, including hydroxychloroquine and colchicine
- Clinical trials
Following this webinar, participants will be able to make informed choices of pharmacological treatments for patients with COVID-19, based on a rigorous assessment of the best available evidence. They will understand the living character of this document and the importance of ongoing and future research to inform its next iterations.
Diseases / methods
- Respiratory infections
- Respiratory physicians
- Infectious disease specialists
- Internal medicine specialists
- Clinical researchers
- Allied healthcare professionals